Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Research

• Publication date

  2004-05-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/0008-5472.CAN-04-0204PMID 15150125
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes.

  2004cited by this paper
• A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer

  2004cited by this paper
• Flavopiridol inhibits the Growth of GL261 Gliomas In Vivo: Implications for Malignant Glioma Therapy

  2004cited by this paper
• Cdk2 as a Master of S phase Entry: Fact or Fake?

  2004cited by this paper
• Novel Small Molecule Cyclin-Dependent Kinases Modulators in Human Clinical Trials

  2003cited by this paper
• Phase II study of flavopiridol in patients with advanced colorectal cancer.

  2003cited by this paper
• Bisindolylmaleimide IX Induces Reversible and Time-Dependent Tumor Necrosis Factor Receptor Family-Mediated Caspase Activation and Cell Death.

  2003cited by this paper
• Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1.

  2003cited by this paper
• Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway.

  2003cited by this paper
• Bisindolymaleimide IX Induces Reversible and Time-Dependent Tumor Necrosis Factor Receptor Family-Mediated Caspase Activation and Cell Death

  2003cited by this paper
• Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.

  2003cited by this paper
• Proliferation of cancer cells despite CDK2 inhibition.

  2003cited by this paper
• Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.

  2003cited by this paper
• Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.

  2003cited by this paper
• Leukemic and Non-Leukemic Lymphocytes from Patients with Li Fraumeni Syndrome Demonstrate Loss of p53 Function, Bcl-2 Family Dysregulation and Intrinsic Resistance to Conventional Chemotherapeutic Drugs But Not Flavopiridol

  2003cited by this paper
• Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C.

  2003cited by this paper
• Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice

  2003cited by this paper
• Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.

  2003cited by this paper
• Defects in the apoptotic machinery of cancer cells: role in drug resistance.

  2003cited by this paper
• Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

  2002cited by this paper
• Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.

  2002cited by this paper
• Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.

  2002cited by this paper
• CDK Inhibitors: Cell Cycle Arrest Versus Apoptosis

  2002cited by this paper
• The Cyclin-Dependent Kinase Inhibitor Butyrolactone Is a Potent Inhibitor of p21WAF1/CIP1 Expression

  2002cited by this paper
• The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.

  2002cited by this paper
• An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis*

  2002cited by this paper
• p53: An Internal Investigation

  2002cited by this paper
• Inhibition of Transcription Results in Accumulation of Wt p53 Followed by Delayed Outburst of p53-Inducible Proteins: p53 as a Sensor of Transcriptional Integrity

  2002cited by this paper
• Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

  2002cited by this paper
• The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.

  2002cited by this paper
• Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence

  2002cited by this paper
• Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.

  2001influential reference
• Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.

  2001cited by this paper
• Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

  2001influential reference
• Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo *

  2001cited by this paper
• The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.

  2001cited by this paper
• Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

  2000cited by this paper
• Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.

  2000cited by this paper
• Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study.

  2000cited by this paper
• Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.

  2000cited by this paper
• P-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II

  2000cited by this paper
• Flavopiridol binds to duplex DNA.

  2000cited by this paper
• RNA synthesis block by 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells

  1999cited by this paper
• Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.

  1999cited by this paper
• Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.

  1999cited by this paper
• Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia

  1999cited by this paper
• Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.

  1999cited by this paper
• Apoptosis and drug response.

  1999cited by this paper
• Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.

  1999cited by this paper
• Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol.

  1998cited by this paper
• Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.

  1998cited by this paper
• Nuclear Factor kB-independent Cytoprotective Pathways Originating at Tumor Necrosis Factor Receptor-associated Factor 2*

  1998cited by this paper
• NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.

  1998cited by this paper
• Identification of multiple cyclin subunits of human P-TEFb.

  1998cited by this paper
• Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.

  1998cited by this paper
• The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines.

  1997cited by this paper
• [CDK inhibitors].

  1997cited by this paper
• Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

  1996cited by this paper
• Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.

  1996cited by this paper
• Actinomycin D as the primary agent for gestational trophoblastic disease

  1975cited by this paper

• Synergistic modulation of p53-HMGB1 complex and its binding to DNA: The role of nanotechnology in overcoming cancer drug resistance; A literature review and in-silico analysis.

  2025cites this paper
• CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation.

  2025cites this paper
• Design and Synthesis of Topoisomerases-Histone Deacetylase Dual Targeted Quinoline-Bridged Hydroxamates as Anticancer Agents.

  2025cites this paper
• Structure-Guided Discovery of Novel N4-(Substituted Thiazol-2-yl)-N2-(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability.

  2025cites this paper
• Conofolidine: A Natural Plant Alkaloid That Causes Apoptosis and Senescence in Cancer Cells

  2024cites this paper
• Distinct states of nucleolar stress induced by anticancer drugs

  2023cites this paper
• Chemopreventive Potential of Dietary Nanonutraceuticals for Prostate Cancer: An Extensive Review

  2022cites this paper
• Colon cancer and colorectal cancer: Prevention and treatment by potential natural products.

  2022cites this paper
• A rohitukine derivative IIIM‐290 induces p53 dependent mitochondrial apoptosis in acute lymphoblastic leukemia cells

  2021influential citation
• Immortalization of human primary prostate epithelial cells via CRISPR inactivation of the CDKN2A locus and expression of telomerase

  2020cites this paper
• The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma

  2020cites this paper
• CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells

  2020cites this paper
• Hypoxia-induced GBE1 expression promotes tumor progression through metabolic reprogramming in lung adenocarcinoma

  2020cites this paper
• NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy

  2019cites this paper
• Iduna protects HT22 cells by inhibiting parthanatos: The role of the p53-MDM2 pathway.

  2019cites this paper
• Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine

  2018cites this paper
• Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

  2017influential citation
• p53 dynamics in response to DNA damage vary across cell lines and are shaped by efficiency of DNA repair and activity of the kinase ATM

  2017cites this paper
• Conservation and Divergence of p53 Oscillation Dynamics across Species.

  2017cites this paper
• Flavopiridol: An Old Drug With New Perspectives? Implication for Development of New Drugs

  2017cites this paper
• Flavopiridol's antiproliferative effects in glioblastoma multiforme.

  2016cites this paper
• Targeted Delivery of Nutraceuticals Using Nanoparticles

  2016cites this paper
• Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation

  2015cites this paper
• Disruption of DNA Repair by Cell Cycle and Transcriptional CDK Inhibition

  2015cites this paper
• Characterization of a Pyrazolo[4,3‐d]pyrimidine Inhibitor of Cyclin‐Dependent Kinases 2 and 5 and Aurora A With Pro‐Apoptotic and Anti‐Angiogenic Activity In Vitro

  2015cites this paper
• The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

  2015cites this paper
• The rearrangement of tosylated flavones to 1′-(alkylamino)aurones with primary amines

  2015cites this paper
• Evidence for transcriptional interference in a dual-luciferase reporter system

  2015cites this paper
• NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect

  2014cites this paper
• Nutraceuticals as potential therapeutic agents for colon cancer: a review

  2014cites this paper
• Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism

  2014cites this paper
• Tumor Vasculature-Targeted Recombinant Mutated Human TNF-α Enhanced the Antitumor Activity of Doxorubicin by Increasing Tumor Vessel Permeability in Mouse Xenograft Models

  2014cites this paper
• MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation

  2014cites this paper
• Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73

  2014cites this paper
• A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.

  2013cites this paper
• Effects of alvocidib and carboplatin on ovarian cancer cells in vitro.

  2013cites this paper
• Moscatilin Induces Apoptosis and Mitotic Catastrophe in Human Esophageal Cancer Cells

  2013cites this paper
• Upstream Targets in the p53 Pathway

  2013cites this paper
• p53 in the Clinics

  2013cites this paper
• Implication of transcriptional repression in compound C-induced apoptosis in cancer cells

  2013cites this paper
• Role of cyclin B1 levels in DNA damage and DNA damage-induced senescence.

  2013cites this paper
• Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells

  2012cites this paper
• Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development

  2012cites this paper
• Cyclin-dependent kinase modulators and cancer therapy.

  2012cites this paper
• Cyclin-Dependent Kinase Modulators and Cancer Therapy

  2012influential citation
• Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms.

  2012cites this paper
• Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells

  2012cites this paper
• Identification of HEXIM1 as a Positive Regulator of p53*

  2012cites this paper
• Combination of flavopiridol and embelin effectively inhibit cell growth in hepatocellular carcinoma depending on regulatory relationship between CDK6 and XIAP

  2012cites this paper
• luteolincolon cancer cells by the dietary compound Induction of cell cycle arrest and apoptosis in HT-29

  2012cites this paper
• The selective P-TEFb inhibitor CAN508 targets angiogenesis.

  2011cites this paper
• The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications

  2011cites this paper
• NPMc+ AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds

  2011cites this paper
• Inhibiting eukaryotic transcription. Which compound to choose? How to evaluate its activity?

  2011cites this paper
• Systemic use of tumor necrosis factor alpha as an anticancer agent

  2011cites this paper
• Identification of Kinase Inhibitors that Target Transcription Initiation by RNA Polymerase II

  2011cites this paper
• Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen

  2010cites this paper
• Nucleostemin

  2010cites this paper
• Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.

  2010cites this paper
• Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy.

  2010cites this paper
• Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

  2010cites this paper
• Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells

  2010cites this paper
• Cyclin-dependent kinase inhibitors as anticancer drugs.

  2010cites this paper
• Discovery and evaluation of anti-cancer agents

  2010cites this paper
• A novel SATB1 binding site in the BCL2 promoter region possesses transcriptional regulatory function

  2010cites this paper
• Targeting Cyclin-Dependent Kinases for Cancer Therapy

  2010cites this paper
• Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors

  2010cites this paper
• MITOTIC SLIPPAGE IN NONCANCER CELLS INDUCED BY A MICROTUBULE DISRUPTOR, DISORAZOLE C1, AND THE NOVEL ROLE FOR GPIBA IN CYTOKINESIS AND TETRAPLOIDIZATION IN CANCER CELLS

  2010cites this paper
• p53-based cancer therapy.

  2010cites this paper
• Novel HIV-1 therapeutics through targeting altered host cell pathways

  2009cites this paper
• Functional p53 in cells contributes to the anticancer effect of the cyclin‐dependent kinase inhibitor roscovitine

  2009cites this paper
• Inhibition of transcription by platinum antitumor compounds.

  2009cites this paper
• Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer

  2009cites this paper
• Selective Cyclin‐Dependent Kinase Inhibitors Discriminating between Cell Cycle and Transcriptional Kinases

  2009cites this paper
• Involvement of p21Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells.

  2009cites this paper
• CDK9 a potential target for drug development.

  2008cites this paper
• Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis

  2008cites this paper
• Purvalanol A induces apoptosis and downregulation of antiapoptotic proteins through abrogation of phosphorylation of JAK2/STAT3 and RNA polymerase II

  2008cites this paper
• Transcriptional inhibitors, p53 and apoptoss.

  2008influential citation
• “Targeting the absence” and therapeutic engineering for cancer therapy

  2008cites this paper
• Progress in the evaluation of CDK inhibitors as anti-tumor agents.

  2008cites this paper
• Strategies to enhance the anticancer potential of TNF.

  2008cites this paper
• Silencing of the transcription factor KLF6 by siRNA leads to cell cycle arrest and sensitizes cells to apoptosis induced by DNA damage

  2008cites this paper
• Updates on p53: modulation of p53 degradation as a therapeutic approach

  2008cites this paper
• The cell cycle molecules behind neurodegeneration in Alzheimer's disease: perspectives for drug development.

  2008cites this paper
• Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3β with p53

  2008cites this paper
• Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways

  2008cites this paper
• Differential sensitivity of human colon cancer cell lines to the nucleoside analogs ARC and DRB

  2008cites this paper
• TNF-α-induced inhibition of proliferation in human glioma cells

  2007cites this paper
• Towards the development of tumor necrosis factor (TNF) sensitizers: making TNF work against cancer.

  2007cites this paper
• Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin.

  2007cites this paper
• HEXIM1 and the Control of Transcription Elongation: From Cancer and Inflammation to AIDS and Cardiac Hypertrophy

  2007cites this paper
• R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy

  2007cites this paper
• p21 (CDKN1A) is a Negative Regulator of p53 Stability

  2007cites this paper
• P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents

  2007cites this paper
• The Cyclin-Dependent Kinase Inhibitor Seliciclib (R-roscovitine; CYC202) Decreases the Expression of Mitotic Control Genes and Prevents Entry into Mitosis

  2007cites this paper
• In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia

  2007influential citation
• Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development

  2007influential citation
• Mitotic Arrest and Cell Fate: Why and How Mitotic Inhibition of Transcription Drives Mutually Exclusive Events

  2007cites this paper
• Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells

  2007cites this paper